1. Home
  2. MIRM vs TOWN Comparison

MIRM vs TOWN Comparison

Compare MIRM & TOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • TOWN
  • Stock Information
  • Founded
  • MIRM 2018
  • TOWN 1998
  • Country
  • MIRM United States
  • TOWN United States
  • Employees
  • MIRM N/A
  • TOWN N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • TOWN Major Banks
  • Sector
  • MIRM Health Care
  • TOWN Finance
  • Exchange
  • MIRM Nasdaq
  • TOWN Nasdaq
  • Market Cap
  • MIRM 3.3B
  • TOWN 2.8B
  • IPO Year
  • MIRM 2019
  • TOWN 1999
  • Fundamental
  • Price
  • MIRM $73.14
  • TOWN $35.14
  • Analyst Decision
  • MIRM Strong Buy
  • TOWN Buy
  • Analyst Count
  • MIRM 10
  • TOWN 2
  • Target Price
  • MIRM $74.20
  • TOWN $40.50
  • AVG Volume (30 Days)
  • MIRM 679.0K
  • TOWN 407.2K
  • Earning Date
  • MIRM 11-11-2025
  • TOWN 10-22-2025
  • Dividend Yield
  • MIRM N/A
  • TOWN 3.08%
  • EPS Growth
  • MIRM N/A
  • TOWN 14.10
  • EPS
  • MIRM N/A
  • TOWN 2.30
  • Revenue
  • MIRM $429,161,000.00
  • TOWN $741,828,000.00
  • Revenue This Year
  • MIRM $53.08
  • TOWN $23.73
  • Revenue Next Year
  • MIRM $20.45
  • TOWN $21.53
  • P/E Ratio
  • MIRM N/A
  • TOWN $15.23
  • Revenue Growth
  • MIRM 62.33
  • TOWN 11.04
  • 52 Week Low
  • MIRM $36.86
  • TOWN $29.43
  • 52 Week High
  • MIRM $78.10
  • TOWN $38.28
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 58.57
  • TOWN 40.39
  • Support Level
  • MIRM $73.35
  • TOWN $34.97
  • Resistance Level
  • MIRM $74.99
  • TOWN $36.62
  • Average True Range (ATR)
  • MIRM 2.37
  • TOWN 0.64
  • MACD
  • MIRM -0.94
  • TOWN -0.19
  • Stochastic Oscillator
  • MIRM 20.40
  • TOWN 8.10

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About TOWN TowneBank

Towne Bank is a financial services company that places special emphasis on serving the financial needs of individuals, commercial enterprises, and professionals, offering retail and commercial banking services to numerous markets in Virginia and North Carolina. The company has three reportable segments: the Banking Segment provides loan and deposit services to retail and commercial customers and provides commercial mortgage brokerage services and investment and asset management services, and the Realty Segment provides residential real estate services and mortgage loans. It also provides resort property management and residential and commercial title insurance, and the Insurance Segment provides a wide array of insurance products, including property, casualty, life, and health insurance.

Share on Social Networks: